Omalizumab versus 'usual care': results from a naturalistic longitudinal study in routine care

International Archives of Allergy and Immunology
H-U WittchenO Riedel

Abstract

It is unclear how far the superior efficacy of omalizumab, established in randomized controlled clinical trials of patients with severe allergic asthma (SAA), translates into routine practice and when compared to matched controls. New-onset omalizumab-treated (OT) patients with SAA (n = 53) were compared to a matched control group of usual-care (UC) patients (n = 53). Treatment and procedures were naturalistic. Subsequent to a baseline assessment, patients were followed up over at least 6 months with at least two follow-up assessments. Primary clinical outcomes were the number of asthma attacks, persistence of asthma symptoms and degree of control [asthma control test (ACT), Global Initiative for Asthma]. Secondary outcome criteria were quality of life (Euro-Qol 5D) and number of medications. For each outcome we compared within-group effects from baseline to 6-month follow-up as well as between-group effects. OT patients showed significant improvements in number [effect size (ES) = 0.03] and frequency (ES = 0.04) of asthma attacks as well as asthma control (ES = 0.09), whereas controls revealed no significant improvements in these measures. Further improvements in the OT group were found for 'perceived control always' (ACT, p =...Continue Reading

References

Jun 1, 1997·American Journal of Respiratory and Critical Care Medicine·J V FahyH A Boushey
Mar 9, 1999·The Journal of Allergy and Clinical Immunology·S Spector
Jun 16, 2000·The Journal of Allergy and Clinical Immunology·P B WilliamsT J Sullivan
Sep 1, 2001·The European Respiratory Journal·M SolèrG Della Cioppa
Aug 9, 2002·The European Respiratory Journal·R BuhlG Della Cioppa
Mar 9, 2006·The Journal of Allergy and Clinical Immunology·Michael SchatzPriti Jhingran
Nov 30, 2006·Psychosomatic Medicine·Thomas RitzMartin Edwards
Oct 9, 2007·Respiratory Medicine·Mathieu MolimardVincent Le Gros
Mar 24, 2009·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·J CorrenP Jimenez
Apr 14, 2009·Respiratory Medicine·Stephen HolgatePablo Jimenez
Aug 10, 2011·Current Medical Research and Opinion·P KardosUNKNOWN sap-NEEDS study group

❮ Previous
Next ❯

Citations

Dec 17, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Rita FariaStephen Palmer
Feb 3, 2015·Pulmonary Pharmacology & Therapeutics·Marco CaminatiErminia Ridolo
May 2, 2017·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Zahi NachefM Jeffery Mador
May 18, 2018·International Archives of Allergy and Immunology·Arzu YorgancıoğluAhmet Erdoğdu
Aug 27, 2016·BMC Pulmonary Medicine·M CaminatiUNKNOWN North East Omalizumab Network study group
Dec 15, 2020·Expert Review of Clinical Immunology·Kenneth M FaulknerChristopher S Lee
Jan 25, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Jean BousquetFrancis Nissen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.